Instead of pursuing novel biological targets, Scape Bio's initial strategy focuses on de-risking its platform. They target GPCRs already clinically validated by existing small-molecule drugs but that suffer from off-target toxicity or selectivity problems. This allows them to prove their mini-protein modality by creating a superior version of a known therapeutic mechanism.

AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

NewLimit combines artificial intelligence with high-throughput biology in a virtuous cycle. Their AI model, Ambrosia, predicts which gene combinations will be effective. These predictions are then tested in thousands of parallel experiments, which in turn generate massive datasets to further train and refine the AI, accelerating discovery.

AI's impact isn't one magic bullet. It will accelerate drug discovery by enhancing multiple stages simultaneously: biasing protein drug candidates to fold correctly, improving their targeting and stability, and enabling the synthesis and testing of massive libraries in parallel. This multi-pronged optimization will create an exponential effect.

Instead of using AI for pure discovery, Variant Bio applies it to a specific bottleneck: data overwhelm. With over 25,000 gene associations per search, they deploy AI agents to sift through proprietary data, identify findings absent from existing literature, and flag novel drug targets for human researchers.

De novo AI is proving its value against notoriously difficult targets. Panelists from major pharmaceutical companies confirmed that these methods are achieving early, promising successes against targets like GPCRs, which have historically been challenging for conventional antibody discovery platforms.

Haya's AI platform is differentiated by its focus on deconvoluting the "dark genome" to identify completely novel, "first-in-biology" targets. This contrasts with AI applications that merely optimize molecules for known biological pathways or targets.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.

The platform's generative nature produces a library of viable antibody candidates for a single target, not just one. This optionality is a key advantage, allowing the team to select the molecule with the best combination of potency, developability, and target profile.